Promoting Leadership at Achieve Life Sciences
Seattle and Vancouver—Achieve Life Sciences, Inc. (Nasdaq: ACHV), a pioneering late-stage pharmaceutical company, has made an important announcement regarding its leadership team. Ms. Jaime Xinos has been promoted to Chief Commercial Officer, immediately taking on this expanded role. This is a significant step as the company focuses on advancing its plans for cytisinicline, intended for those struggling with nicotine dependence.
Jaime Xinos: A Valuable Asset to Achieve Life Sciences
Since joining Achieve Life Sciences in 2017, Ms. Xinos has played a crucial part as the Executive Vice President of Commercial. In her new capacity, she will be responsible for all commercial operations, facilitating the strategic preparation for the upcoming U.S. launch of cytisinicline. This involves ensuring essential readiness among key stakeholders, including patients, healthcare providers, and payors, which is vital for a successful drug launch following FDA approval.
CEO's Remarks on Ms. Xinos's Promotion
Rick Stewart, the CEO of Achieve Life Sciences, expressed enthusiasm regarding the promotion of Jaime, highlighting her unwavering commitment to the company’s commercial strategies. He emphasized, “Her innovative, patient-first digital strategies are integral to achieving our goals of bringing cytisinicline to market.” Through her leadership, Stewart believes that the company can better facilitate drug readiness, making a significant difference for many individuals coping with smoking and vaping dependencies.
Driving Strategic Partnerships
Under her leadership, Ms. Xinos will also direct Achieve's efforts to establish partnerships with other firms and experts in commercialization. This collaborative strategy is essential, as it addresses the unique challenges faced by small biotech companies introducing their inaugural products. The aim is to offer innovative, value-driven solutions for smooth market entry and long-term success.
Ms. Xinos's Vision for Cytisinicline
In her own words, Xinos stated, “I’m honored to step into this expanded role as Chief Commercial Officer at such a pivotal time for Achieve Life Sciences.” She emphasized the immense potential of cytisinicline, aiming to be the first new FDA-approved treatment for nicotine dependence in almost twenty years. Xinos is determined to focus on cultivating strong collaborations while executing an innovative strategy to enhance patient care.
Experience and Expertise
Ms. Xinos brings a wealth of experience to her new role, boasting close to 25 years in the biotechnology and pharmaceutical sectors. Her background includes significant positions at prestigious organizations such as OncoGenex, Pfizer, Novartis, and Abbott Laboratories. Renowned for her ability to integrate scientific breakthroughs with robust business strategies, she has demonstrated exceptional prowess in developing products across various stages of their lifecycle. Ms. Xinos holds both a Bachelor of Arts and a Master of Business Administration from the University of Illinois, underscoring her solid foundation in education.
About Achieve Life Sciences and Cytisinicline
Achieve Life Sciences is dedicated to combating the global epidemic of smoking and nicotine addiction by advancing cytisinicline's development and commercialization. In the U.S. alone, there are about 29 million adults who still smoke combustible cigarettes. Tobacco use is a leading cause of preventable deaths, accounting for over eight million fatalities worldwide each year, alongside hundreds of thousands of deaths in the U.S.
Moreover, the increasing trend of e-cigarette usage among adults, with more than 11 million engaged in vaping, underscores the urgent need for effective cessation solutions. Cytisinicline emerges as a promising investigational drug candidate that may help combat nicotine addiction. As a plant-based alkaloid, it interacts with nicotinic receptors in the brain, potentially alleviating cravings and altering the reinforcement of nicotine.
Frequently Asked Questions
1. What is Achieve Life Sciences focusing on?
Achieve Life Sciences is concentrating on the development and commercialization of cytisinicline for treating nicotine dependence.
2. Who is the newly appointed Chief Commercial Officer?
Jaime Xinos has been appointed the Chief Commercial Officer of Achieve Life Sciences, promoted from her previous role as Executive Vice President of Commercial.
3. What is cytisinicline?
Cytisinicline is a plant-based alkaloid developed to help treat nicotine addiction, showing promise as an aid for smoking and vaping cessation.
4. How does Achieve Life Sciences plan to prepare for cytisinicline's launch?
The company aims to drive readiness by engaging with key stakeholders such as patients, healthcare providers, and payors to ensure a successful launch.
5. What experience does Jaime Xinos bring to her new role?
Ms. Xinos has nearly 25 years of experience in the biotechnology and pharmaceutical industries, with notable roles at leading companies such as Pfizer and Novartis.
